



Scleroderma | Sclérodermie
Canada | Canada

Annual General Meeting 2020 - 2021

TUESDAY, DECEMBER 7, 2021 – 7PM EST



Scleroderma | Sclérodermie
Canada | Canada

Vision: A World Free of Scleroderma

Mission: To Enrich the Quality of Life for Scleroderma Patients

Pillars:

1. Advocacy
2. Patient Support
3. Education
4. Research

Scleroderma Canada Board of Directors 2020 - 2021

Executive Committee:

Colin Magee, President
Jason Doucette, Past President

Committee Chairs:

Maureen Worrón-Sauvé, Advocacy
Vanessa Cook, Patient Support
Lyna Phung, Membership Engagement

Provincial Representatives:

Jason Doucette, Atlantic
Gillian Little, Alberta
Tracey Magee, Saskatchewan
Silvia Petrozza, Ontario

Meeting Agenda

1. Welcome and opening remarks

- a) Introductions
- b) Declaration of quorum
- c) Adoption of agenda

2. Business arising

- a) Acceptance of minutes – 20/21 Board meetings & 19/20 AGM
- b) 2020-2021 AGM Report
- c) Financial committee report:
 - Auditor's report for YE May 31, 2021
 - Appointment of Auditors for YE 21/22
- d) Presentation of new slate for Board of Directors
- e) Announcement of new slate for Board of Directors

3. Adjournment





Scleroderma | Sclérodermie
Canada | Canada

Fundraising Events, 2020 - 2021



2020 Virtual Walk or Run in the Park for Scleroderma



Scleroderma Canada hosted virtual walks in 10 locations in 2020

Scleroderma Atlantic	\$12,140.00
Chapleau, ON	\$320.00
Create Your Own	\$6,125.00
Edmonton, AB	\$11,590.00
Hamilton, ON	\$91,068.00
London, ON	\$17,235.00
Ottawa, ON	\$6,275.00
Regina, SK	\$13,333.00
Saskatoon, SK	\$300.00
Sylvan Lake, AB	\$2,500.00
Toronto, ON	\$33,826.00
Virtual Walk	\$1,905.00

TOTAL:	\$196,717.00
---------------	---------------------





2020 Virtual Walk or Run in the Park for Scleroderma

In light of COVID-19, our 2020 Walk and Run in the Park for Scleroderma became an exclusively virtual event. This allowed patients, caregivers, friends, and family to forge ahead, maintaining an incredible sense of accomplishment and community. Participants leveraged their personal social media platforms to get the word out as we've never seen before. We are incredibly grateful for the response and the support from our communities and wish to give special thanks to the Civiero Family, who matched donations up to \$25,000 along with all other donors.

Traditional media platforms also played an important role in the success of the virtual event. There were several radio and TV interviews recognizing the important work being done to raise awareness, advance patient wellness and support research to find a cure for scleroderma during Scleroderma Awareness Month. A total of 19 landmarks were illuminated in honour of June Awareness and World Scleroderma Day.



OCTOBER 5-9, 2020

SCLERODERMA VIRTUAL CONFERENCE

Scleroderma Canada virtually hosted 155 guests at the 19th Bi-Annual National Scleroderma Conference in 2020.

We were honoured to showcase 15 best-in-class speakers, sharing updates on research, initiatives, tools, guidelines, practices, and support networks, in Canada.

We were proud to be able to continue to bring this educational event to our members in uncertain times and are grateful for the opportunity to raise much needed funds for SC.

Please visit Scleroderma Canada's YouTube channel for speaker sessions and conference highlights.



Scleroderma Canada | Sclérodermie Canada



OCTOBER 5-9, 2020

SCLERODERMA VIRTUAL CONFERENCE

“To be able to be a part of this year’s conference is wonderful, as I would not have attended if it were not for technology.”

“It is inspiring to know that there are people who are so concerned and involved with scleroderma research and treatment.”

“Loved and appreciated the personal testimony of patient’s journeys. Sometimes I feel so alone but I have so many “brothers and sisters” on this journey. I leave this conference as I did in Calgary (which was my first time attending) supported, encouraged and motivated. Thank you so much to everyone.”

“This webinar was so well done. The best I have ever participated in. Thank you!”



Scleroderma Canada | Sclérodémie Canada



Scleroderma | Sclérodermie
Canada | Canada

Education

Scleroderma Summit

April 20, 2021

Scleroderma Canada was honoured to receive funding from Mallinckrodt Pharmaceuticals to host a Scleroderma Summit, bringing together nearly 20 leading scleroderma organizations and partners, to discuss the needs within our community, such as:

- Best practices within organizations
- Raising Awareness beyond the month of June

Guest speaker: Dr. Sindhu Johnson


Patient Panel: Maureen Sauvé, Tanya Acorn, Silvia Petrozza, Lyna Phung, Aldo Wright & Beth Miller



Scleroderma Canada | Sclérodémie Canada

Scleroderma Canada in Partnership with Mallinckrodt Presents our Spring Learning Series

› 3 Facebook live sessions Promoted by Scleroderma Canada



*Living with Scleroderma as a multi-stakeholder meeting with a patient, caregiver, dermatologist, and rheumatologist.

Canadian Scleroderma Information Series

Mallinckrodt Pharmaceuticals sponsored a series of educational webinars with Scleroderma Canada. We were pleased to share this opportunity with our provincial partners for the following events:

February 11, 2021: Dealing with COVID & Vaccines
Hosted by Scleroderma Canada

March 23, 2021: Oral & Dental Care in Scleroderma
Hosted by The Scleroderma Association of Saskatchewan & Scleroderma Alberta

April 18, 2021: Getting active - Where to start & how to keep going
Hosted by Atlantic Canada

Patient Education Forums 2020

We were grateful to once again secure funding from Boehringer- Ingelheim to assist with the planning and execution of a Patient Education Forum, in 2020.

The SSO hosted it's 6th Annual Patient Forum on October 27, 2020. Due to COVID-19 restrictions, this event was hosted virtually to maintain the safety of more than 85 participants. We heard from 6 individual speakers from McMaster University, along with an open discussion panel in which patients could inquire about COVID-19 as it relates to their scleroderma.

Many thanks to B.I. and the HSG for their ongoing support to bring this valuable content to our members.



2020 Virtual Legislative Meetings, Ontario



2020 Virtual Legislative Meetings, Alberta



Ontario: November 16 – 20, 2020
Alberta: November 25 – 27, 2020

SC used funds secured from Boehringer Ingelheim to coordinate extremely successful virtual advocacy meetings. With the assistance of Temple Scott Associates, we were able to schedule almost 30 meetings, between the two provinces.



In Alberta, we held 9 meetings with MLA's and Staff, including one with Leela Aheer, Deputy Leader of the United Conservative Party and

In Ontario, we held 19 meetings with MPP's and Staff and had the distinct privilege to secure a 30-minute meeting with Minister of Health, Christine Elliott.

Discussions included what government can do to help with drug approvals for our patients. Specifically, we are working to improve access to PDE5i (commonly known as Viagra). We look forward to sharing positive outcomes as soon as possible.



Grants in 2020

Thanks to the generous support of the following groups Scleroderma Canada was able to continue to offer patient education, facilitate support groups, raise awareness and advocate for our members throughout the country.

- Boehringer Ingelheim Canada \$192,000
- Boehringer Ingelheim International \$50,000
- Janssen \$20,000
- Mallinckrodt \$15,000

Financial Statement

A person wearing a white long-sleeved shirt is seated at a desk, signing a document with a black pen. Their left hand rests on the paper. The background is blurred, showing an office setting with a window and some plants.

Year ended May 31, 2021

SCLERODERMA CANADA

Financial Statements
for the Year Ended May 31, 2021
and Independent Auditor's Report to the Board of Directors

Draft

SCLERODERMA CANADA
FINANCIAL STATEMENTS
MAY 31, 2021

CONTENTS

Independent Auditor's Report to the Board of Directors.....	1 - 2
Statement of Operations and Changes In Net Assets.....	3
Statement of Financial Position.....	4
Statement of Cash Flows.....	5
Notes to the Financial Statements.....	6 - 10



DURWARD JONES BARKWELL
& COMPANY LLP

Big enough to know. SMALL ENOUGH TO CARE.

570 Highland Road West
Unit 1
Hamilton, ON L8W 0C4
T. 905.525.9520
TF. 866.358.8240
F. 905.522.3113

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Scleroderma Canada:

Qualified Opinion

We have audited the accompanying financial statements of Scleroderma Canada (the Entity), which comprise the statement of financial position as at May 31, 2021 and the statements of operations and changes in net assets and of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the financial statements present fairly, in all material respects, the financial position of the Entity as at May 31, 2021, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

In common with many not-for-profit organizations, the Entity derives revenue from donations, sponsorships and fundraising activities the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of the Entity. Therefore, we were not able to determine whether any adjustments might be necessary to donations, sponsorships or fundraising revenue, excess of revenue over expenses, and cash flows from operations for the years ended May 31, 2021 and 2020, current assets as at May 31, 2021 and 2020, and net assets as at June 1 and May 31 for both the 2021 and 2020 year ends. The audit opinion on the financial statements for the year ended May 31, 2020 was modified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained in our audit is sufficient and appropriate to provide a basis for our qualified opinion.

Other Matter

The financial statements of the Entity for the year ended May 31, 2020, prior to the restatement described in Note 2, were audited by another auditor who expressed a qualified opinion on those statements on December 18, 2020.

Responsibilities of Management and Those Charged With Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Durward Jones Barkwell & Company LLP
Licensed Public Accountants

November 30, 2021

SCLERODERMA CANADA
STATEMENT OF OPERATIONS AND CHANGES IN NET ASSETS
YEAR ENDED MAY 31, 2021

3

	2021	2020 (restated) (Note 2)
REVENUE		
Conference sponsorships	\$ 78,576	\$ -
Donations	55,380	102,116
Funding from provincial organizations	5,595	-
Grants	280,987	259,488
June awareness revenue	107,936	133,341
June awareness contributions from provincial organizations	28,881	46,316
Special event revenue	7,752	13,475
	565,107	554,736
EXPENSES		
Conference	40,000	184
Insurance	-	1,927
June awareness expenses	7,827	15,505
June awareness contributions to provincial organizations	78,030	87,319
Meetings and travel	149	1,517
Occupancy costs	2,356	2,264
Office	37,011	12,779
Platform fees	1,955	11,474
Professional fees	18,143	13,518
Provincial funding	132,147	192,840
Public awareness and advocacy	22,424	55,852
Research	105,000	50,000
Salaries and benefits	10,209	68,784
Telephone	1,592	1,681
	456,843	515,644
EXCESS OF REVENUE OVER EXPENSES	108,264	39,092
UNRESTRICTED NET ASSETS, BEGINNING OF YEAR		
As previously reported	85,569	55,809
Impact of restatement (Note 2)	-	(9,332)
	85,569	46,477
UNRESTRICTED NET ASSETS, END OF YEAR	\$ 193,833	\$ 85,569

SCLERODERMA CANADA
STATEMENT OF FINANCIAL POSITION
MAY 31, 2021

4

	2021	2020 (restated) (Note 2)
ASSETS		
Current assets		
Cash	\$ 358,957	\$ 238,805
Term deposit	49,082	49,082
Sales tax recoverable	4,557	24,164
Prepaid expenses	742	95
	\$ 413,338	\$ 312,146
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	\$ 9,293	\$ 14,686
Due to Scleroderma Society of Ontario (Note 3)	882	51,986
Deferred revenue (Note 4)	149,330	159,905
	159,505	226,577
Canada Emergency Business Account program loan (Note 5)	60,000	-
	219,505	226,577
UNRESTRICTED NET ASSETS	193,833	85,569
	\$ 413,338	\$ 312,146

Approved by the Board:

..... Director Director

SCLERODERMA CANADA

STATEMENT OF CASH FLOWS
YEAR ENDED MAY 31, 2021

5

	2021	2020 (restated) (Note 2)
OPERATING ACTIVITIES		
Excess of revenue over expenses	\$ 108,264	\$ 39,092
Changes in non-cash operating assets and liabilities		
Sales tax recoverable	19,607	(4,290)
Prepaid expenses	(647)	11,313
Accounts payable and accrued liabilities	(5,393)	(3,126)
Due to Scleroderma Society of Ontario	(51,104)	71,230
Deferred revenue	(10,575)	(62,165)
	60,152	52,054
INVESTING ACTIVITY		
Increase in term deposit	-	14,514
FINANCING ACTIVITY		
Canada Emergency Business Account program loan	60,000	-
INCREASE IN CASH	120,152	66,568
CASH, BEGINNING OF YEAR	238,805	172,237
CASH, END OF YEAR	\$ 358,957	\$ 238,805

1. SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

Basis of accounting

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations.

Nature of business

Scleroderma Canada ("the Organization") is a non-profit established to promote public awareness, provide education and support and fund research. The Organization was incorporated on April 10, 2000, without share capital, under the Canada Corporations Act and is a registered charity under the Income Tax Act.

Revenue recognition

The Organization follows the deferral method of accounting for contributions which include donations, core funding and grants. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Externally restricted contributions are recognized as revenue in the year in which the related expenses are incurred. To the extent such contributions are unspent at year end, they are presented as deferred revenue on the statement of financial position.

Conference sponsorships are recognized as revenue in the year in which the conference takes place. Sponsorships received in advance are recognized as deferred revenue until the conference takes place.

Special event revenues, which include June Awareness and education forum revenues are recognized as revenue in the year in which the special event or forum takes place. Revenue received in advance is recognized as deferred revenue until the special event or forum takes place.

Government assistance

Government assistance related to current expenses or revenues are included in the statement of operations for the year. When government assistance relates to expenses of future accounting periods, the appropriate amounts shall be deferred and amortized to income as related expenses are incurred.

Contributed services

The Organization relies on the services of volunteers but does not record the value of contributed services as the amounts are not readily determinable.

Income taxes

No provision for income taxes is required as the Organization is exempt from income taxes under Section 149(1)(l) of the Canadian Income Tax Act.

Financial instruments

(a) Measurement of financial instruments

The Organization initially measures its financial assets and financial liabilities at their fair value adjusted by, in the case of a financial instrument that will not be measured subsequently at fair value, the amount of transaction costs directly attributed to the instrument.

The Organization subsequently measures all its financial assets and financial liabilities at amortized cost, except for equity securities quoted in an active market, which are subsequently measured at fair value. Changes in fair value are recognized in the statement of operations.

Financial assets measured at amortized cost include cash, term deposit and sales tax recoverable.

Financial liabilities measured at amortized cost include accounts payable and accrued liabilities and Canada Emergency Business Account program loan.

SCLERODERMA CANADA
NOTES TO THE FINANCIAL STATEMENTS
MAY 31, 2021

7

(b) Impairment

Financial assets measured at amortized cost are tested for impairment when there are indicators of possible impairment. When a significant adverse change has occurred during the period in the expected timing or amount of future cash flows from the financial asset or group of assets, a write-down is recognized in the statement of operations. The write-down reflects the difference between the carrying amount and the higher of:

- (a) the present value of the cash flows expected to be generated by the asset or group of assets;
- (b) the amount that could be realized by selling the asset or group of assets;
- (c) the net realizable value of any collateral held to secure repayment of the asset or group of assets.

When events occurring after the impairment confirm that a reversal is necessary, the reversal is recognized in the statement of operations up to the amount of the previously recognized impairment.

Use of estimates

The preparation of financial statements in accordance with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management's best estimates, as additional information becomes available in the future. Significant estimates and assumptions are used when accounting for items such as revenue recognition and accrued liabilities.

2. RESTATEMENT OF PRIOR YEAR'S FIGURES

A correction for the overstatement of sales tax recoverable has resulted in the restatement of certain prior year's figures. Opening net assets as at April 1, 2019 and sales tax recoverable as at May 31, 2020 were restated and decreased by \$9,332.

3. DUE TO SCLERODERMA SOCIETY OF ONTARIO

Amounts due to Scleroderma Society of Ontario are non-interest bearing, unsecured and due on demand.

4. DEFERRED REVENUE

Deferred revenue consists of restricted contributions and unspent funding as follows:

	Opening Balance	Received	Incurred	Ending Balance
Conference sponsorships	\$ 68,576	\$ 10,000	\$ 78,576	\$ -
Externally restricted donations	70,512	328,314	280,987	117,839
Special events	20,817	118,610	107,936	31,491
	<u>\$ 159,905</u>	<u>\$ 456,924</u>	<u>\$ 467,499</u>	<u>\$ 149,330</u>

5. CANADA EMERGENCY BUSINESS ACCOUNT PROGRAM LOAN

Originally, this program provided interest-free loans of up to \$40,000 to small businesses and not-for-profits, to help cover their operating costs during a period where their revenues have been temporarily reduced due to the economic impacts of the COVID-19 virus. A registered business must meet certain eligibility criteria as outlined by the Federal Government. The loaned funds may only be used to pay for operating costs that cannot be deferred, such as payroll, rent, utilities, insurance, debt payments and property tax.

The expectation is that the \$40,000 loan is interest free. \$10,000, which is 25% of the loan, is eligible for complete forgiveness if \$30,000 is fully repaid on or before December 31, 2022. Unpaid amounts remaining after this date may be converted into term loans or credit lines, the availability and terms of which vary across financial institutions.

As of December 4, 2020, eligible small businesses and not-for-profits were able to apply for the expanded Canada Emergency Business Account loan for an additional \$20,000 in financing of which \$10,000 can be forgiven. New applications for \$60,000 in financing were available also. The organization has applied for this expanded loan. Repaying the balance of the loan on or before December 31, 2022 will result in loan forgiveness of 33% (up to \$20,000).

6. CANADA EMERGENCY WAGE SUBSIDY

In the current year, the Company applied for \$9,888 (2020 - \$6,135) under the Canada Emergency Wage Subsidy as a result of their decline in revenue attributed to the COVID-19 pandemic. Entities must satisfy certain eligibility criteria, including among others a significant decline in revenue as compared to earlier periods. The subsidy received has been deducted from the salaries and benefits expense.

7. RELATED PARTY TRANSACTIONS

The Organization has entered into agreements with four Provincial Scleroderma Societies (the "Partners") in relation to the June Awareness events. The Partners have agreed to provide 50% of their net proceeds from walk/run/bike and other events pertaining to June Awareness to the Organization. Total revenue received from the Provinces in relation to June Awareness is \$28,881 (2020 - \$46,316). In addition, funds received from the national campaign are allocated to the Provinces. During the year, \$78,030 (2020 - \$87,319) was contributed.

During the year, the Organization recognized \$5,595 (2020 - \$Nil) of funding from a provincial Scleroderma society.

The Organization has common management with the Scleroderma Society of Ontario. During the year, the Organization reimbursed Scleroderma Society of Ontario for management services costs in the amount of \$30,000 (2020 - \$Nil), which is included in office expenses.

During the year, the Organization paid \$40,000 (2020 - \$Nil) to the Scleroderma Society of Ontario for expenses related to holding its annual conference.

During the year, the Organization contributed \$132,147 (2020 - \$192,840) in funding to various provincial Scleroderma Societies.

These transactions occurred in the normal course of operations and are recorded at the exchange amount as agreed to by the related parties.

SCLERODERMA CANADA
NOTES TO THE FINANCIAL STATEMENTS
MAY 31, 2021

9

8. FINANCIAL RISK MANAGEMENT

The Organization has a comprehensive risk management framework to monitor, evaluate and manage the principal risks assumed with financial instruments. The risks that arise from transacting financial instruments include interest rate risk, market (other price) risk, currency risk, credit risk, and liquidity risk. Price risk arises from changes in interest rates, foreign currency exchange rates and market prices.

It is management's opinion that the Organization is not exposed to significant interest rate, market, currency, credit and liquidity risks arising from its financial instruments.

9. SOURCES OF CONTRIBUTIONS

During the year, donations and grant revenues were received from the following sources:

	2021	2020
Community groups, churches and other charities	\$ 5,000	\$ -
Corporations	253,862	262,704
Foundations	37,298	-
Individuals	40,207	98,900
	<u>\$ 336,367</u>	<u>\$ 361,604</u>
Balance consists of:		
Revenue - Donations	\$ 55,380	\$ 102,116
Revenue - Grants	280,987	259,488
	<u>\$ 336,367</u>	<u>\$ 361,604</u>

10. COMPARATIVE FIGURES

Certain of the prior year's figures have been reclassified to conform to the current year's financial statement presentation.

The comparative figures for the year ended May 31, 2020, excluding the adjustments that were applied to restate certain comparative information as disclosed in Note 2, were reported on by other auditors.

11. IMPACT OF COVID-19 PANDEMIC

Since December 31, 2019, the spread of COVID-19 has severely impacted many local economies around the globe. In many countries, including Canada, businesses are being forced to cease or limit operations for long or indefinite periods of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of nonessential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown.

The Organization has determined that adjustments to the financial statements are not required as a result of these events. Accordingly, the financial position and results of operations as of and for the year ended May 31, 2021 have not been adjusted to reflect their impact. The duration and impact of the COVID-19 pandemic, as well as the effectiveness of government and central bank responses, remains unclear at this time. It is not possible to reliably estimate the duration and severity of these consequences, as well as their impact on the financial position and results of the Organization for future periods.

Scleroderma Canada Board Slate of Directors 2021 - 2022

Executive Committee:

Colin Magee, President

Jason Doucette, Past President

Committee Chairs:

Maureen Worrone-Sauvé, Advocacy

Vanessa Cook, Patient Support

Lyna Phung, Membership Engagement

Livia Josza, Education

Provincial Representatives:

Jason Doucette, Atlantic

Gillian Little, Alberta

Tracey Magee, Saskatchewan

Silvia Petrozza, Ontario





Scleroderma | Sclérodermie
Canada | Canada

With your support, we look forward to
another successful year.

Thank you!